Exploring the Growing Influenza Diagnostics Market 2021-2026: What You Need to Know | Danaher Corporation (US), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), F. Hoffmann-LA Roche AG (Switzerland), Abbott Laboratories, Inc. (Us)

The Influenza Diagnostics Market is a rapidly growing sector, with technological advancements and increasing awareness about the disease driving the growth of the market. Influenza, commonly known as the flu, is a viral infection that can cause mild to severe symptoms. Early diagnosis and treatment of the flu is essential for preventing its spread and reducing the risk of complications. The global Influenza Diagnostics Market is estimated to grow at a compound annual growth rate of 7.7% from 2021 to 2026.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222985562&utm_source=Openpr&utm_medium=Paid&utm_campaign=Referral

Rising demand for rapid disease diagnosis, increasing prevalence of influenza and growth in influenza research for diagnostic technologies are among the other factors. Emerging economies such as India and Japan are providing lucrative opportunities for the players operating in the influenza diagnostics market.

The Growth in influenza research for diagnostic technologies, increasing prevalence of influenza and rising demand for rapid disease diagnosis are the major factors driving the influenza diagnostic market's growth.

Based on products, the influenza diagnostics market is segmented into test kits and reagents, instruments and other products. In 2020, the test kits and reagents segment accounted for the largest share of the market, mainly due to Rising demand for rapid disease diagnosis and growth in influenza research for diagnostic technologies.

Based on test type, the influenza diagnostics market is segmented into traditional diagnostic test (rapid influenza diagnostic tests, viral culture tests, direct fluorescent antibody test, serological tests) and molecular diagnostic tests (polymerase chain reaction, isothermal nucleic acid amplification tests(transcription-mediated amplification-based assay, loop-mediated isothermal amplification-based assay, nucleic acid sequence-based amplification tests, other isothermal nucleic acid amplification tests) and other molecular diagnostic tests). In 2020, the molecular diagnostic tests segment accounted for the largest share of the market. The large share of this segment can mainly be attributed to the increasing prevalence of influenza and growth in influenza research for diagnostic technologies.

Based on end users, the influenza diagnostics market has been segmented into diagnostic laboratories, hospitals and clinics and other end users. In 2020, the diagnostic laboratories segment accounted for the largest share of market, mainly due to the increasing prevalence of influenza and rising demand for rapid disease diagnosis.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=222985562&utm_source=Openpr&utm_medium=Paid&utm_campaign=Referral

Geographical Growth Scenario:

The global influenza diagnostics market is segmented into five major regions-North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest regional market for market in 2020. The large share of North America in this market can be attributed to the growth in influenza research for diagnostic technologies in the country and increasing prevalence of influenza.

Key Players:

The major players operating in this influenza diagnostics market are Danaher Corporation (US), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), F. Hoffmann-LA Roche AG (Switzerland), Abbott Laboratories, Inc. (Us), Hologic, Inc. (US), bioMérieux SA (France), Quidel Corporation (US), Becton, Dickinson and Company (US), Meridian Bioscience (US), GenMark Diagnostics, Inc. (US), Luminex Corporation (US), Tecanclinica Trading AG (Switzerland), DiaSorin SA (Italy), altona Diagnostics GmbH (Germany), SEKISUI Diagnostics (US), SA Scientific Ltd. (US), Coris BioConcept SPRL (Belgium), ELITech Group (France), Mast Group Ltd. (UK), Genome Diagnostics, Pvt. Ltd. (India), Germaine Laboratories, Inc. (US), Response Biomedical Corp. (Canada). Tauns Laboratories, Inc. (Japan) and 3B BlackBio Biotech India Ltd. (India).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=222985562&utm_source=Openpr&utm_medium=Paid&utm_campaign=Referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.